- Home
- ASPI vs KROS Comparison
ASPI vs KROS Comparison
Compare ASPI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- KROS
- Stock Information
- Founded
- ASPI 2021
- KROS 2015
- Country
- ASPI United States
- KROS United States
- Employees
- ASPI N/A
- KROS N/A
- Industry
- ASPI Major Chemicals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- KROS Health Care
- Exchange
- ASPI Nasdaq
- KROS Nasdaq
- Market Cap
- ASPI 653.4M
- KROS 565.0M
- IPO Year
- ASPI 2022
- KROS 2020
- Fundamental
- Price
- ASPI $9.41
- KROS $14.47
- Analyst Decision
- ASPI Strong Buy
- KROS Buy
- Analyst Count
- ASPI 2
- KROS 13
- Target Price
- ASPI $7.75
- KROS $20.63
- AVG Volume (30 Days)
- ASPI 4.8M
- KROS 442.6K
- Earning Date
- ASPI 08-18-2025
- KROS 08-06-2025
- Dividend Yield
- ASPI N/A
- KROS N/A
- EPS Growth
- ASPI N/A
- KROS N/A
- EPS
- ASPI N/A
- KROS 0.11
- Revenue
- ASPI $4,405,477.00
- KROS $214,713,000.00
- Revenue This Year
- ASPI $512.64
- KROS $5,390.70
- Revenue Next Year
- ASPI $181.15
- KROS N/A
- P/E Ratio
- ASPI N/A
- KROS $132.57
- Revenue Growth
- ASPI 245.97
- KROS 91657.70
- 52 Week Low
- ASPI $1.86
- KROS $9.12
- 52 Week High
- ASPI $10.82
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ASPI 55.83
- KROS 57.73
- Support Level
- ASPI $9.33
- KROS $14.18
- Resistance Level
- ASPI $10.82
- KROS $14.85
- Average True Range (ATR)
- ASPI 0.91
- KROS 0.50
- MACD
- ASPI 0.07
- KROS 0.04
- Stochastic Oscillator
- ASPI 61.37
- KROS 68.46
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.